VIVANI MEDICAL, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.69 USD | -0.59% |
|
+2.41% | +66.67% |
| Mar. 26 | Vivani Medical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Mar. 06 | Vivani Medical, Inc. Appoints Daniel Bradbury to Its Board of Directors | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 93.46M |
|---|---|---|---|---|---|
| Net income 2024 * | -27M | Net income 2025 * | -31M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-3.4
x | P/E ratio 2025 * |
-3.04
x | Employees | 44 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.46% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.73% | ||
| 1 week | +2.41% | ||
| Current month | +4.94% | ||
| 1 month | -22.02% | ||
| 3 months | +68.32% | ||
| 6 months | +63.46% | ||
| Current year | +66.67% |
1 week
1.68
1.82
1 month
1.612.08
Current year
1.007.80
1 year
0.847.80
3 years
0.757.80
5 years
0.757.80
10 years
0.757.80
| Managers | Title | Age | Since |
|---|---|---|---|
Adam Mendelsohn
FOU | Founder | 42 | 03-05-21 |
Brigid Makes
DFI | Director of Finance/CFO | 68 | 22-08-29 |
Truc Le
COO | Chief Operating Officer | - | 22-08-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregg Williams
CHM | Chairman | 65 | 08-12-31 |
Wilford Baker
BRD | Director/Board Member | 81 | 20-12-31 |
Aaron Mendelsohn
BRD | Director/Board Member | 72 | 97-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 1.7 | -1.73% | 38 924 |
| 24-05-07 | 1.73 | -3.35% | 71,729 |
| 24-05-06 | 1.79 | +0.56% | 99,726 |
| 24-05-03 | 1.78 | +3.49% | 74,262 |
| 24-05-02 | 1.72 | +3.61% | 51,919 |
End-of-day quote Nasdaq, May 07, 2024
More quotes
Vivani Medical, Inc. is a preclinical-stage biopharmaceutical company. The Company develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. It is engaged in the development of the Companyâs lead programs NPM-115 and NPM-119, is a GLP-1 implant candidates for the treatment of chronic weight management and patients with type 2 diabetes, respectively. Its other pipeline product candidates include NPM-139, and OKV-119. It uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. It operates through two segments: Biopharm Division and Neuromodulation Division. The Companyâs implant technology, which it refers as NanoPortal, utilizes a space-efficient design that allows a miniaturized implant to provide many months of therapeutic delivery of potent molecules.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.7
USD
Average target price
8
USD
Spread / Average Target
+370.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +66.67% | 93.46M | |
| +9.96% | 125B | |
| -6.95% | 10.97B | |
| +2.70% | 8.99B | |
| -19.67% | 4.86B | |
| +34.49% | 5.38B | |
| +8.18% | 3.43B | |
| -9.55% | 2.78B | |
| -5.57% | 2.22B | |
| -0.60% | 2.21B |
- Stock Market
- Equities
- VANI Stock